Cited 6 times in
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas Without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석구 | - |
dc.contributor.author | 장종희 | - |
dc.date.accessioned | 2020-06-17T00:40:53Z | - |
dc.date.available | 2020-06-17T00:40:53Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/176080 | - |
dc.description.abstract | Purpose: We investigated the efficacy of temozolomide during and after radiotherapy in Korean adults with anaplastic gliomas without 1p/19q co-deletion. Materials and methods: This was a randomized, open-label, phase 2 study and notably the first multicenter trial for Korean grade III glioma patients. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with an Eastern Cooperative Oncology Group performance status of 0-2. Patients were randomized 1:1 to receive radiotherapy alone (60 Gy in 30 fractions of 2 Gy) (control group, n=44) or to receive radiotherapy with concurrent temozolomide (75 mg/m2/day) followed by adjuvant temozolomide (150-200 mg/m2/day for 5 days during six 28-day cycles) (treatment group, n=40). The primary end-point was 2-year progression-free survival (PFS). Seventy patients (83.3%) were available for the analysis of the isocitrate dehydrogenase 1 gene (IDH1) mutation status. Results: The two-year PFS was 42.2% in the treatment group and 37.2% in the control group. Overall survival (OS) did not reach to significant difference between the groups. In multivariable analysis, age was a significant risk factor for PFS (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.04 to 4.16). The IDH1 mutation was the only significant prognostic factor for PFS (HR, 0.28; 95% CI, 0.13 to 0.59) and OS (HR, 0.19; 95% CI, 0.07 to 0.50). Adverse events over grade 3 were seen in 16 patients (40.0%) in the treatment group and were reversible. Conclusion: Concurrent and adjuvant temozolomide in Korean adults with newly diagnosed non-co- deleted anaplastic gliomas showed improved 2-year PFS. The survival benefit of this regimen needs further analysis with long-term follow-up at least more than 10 years. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas Without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학교실) | - |
dc.contributor.googleauthor | Kihwan Hwang | - |
dc.contributor.googleauthor | Tae Min Kim | - |
dc.contributor.googleauthor | Chul-Kee Park | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Tae-Young Jung | - |
dc.contributor.googleauthor | Jin Hee Kim | - |
dc.contributor.googleauthor | Do-Hyun Nam | - |
dc.contributor.googleauthor | Se-Hyuk Kim | - |
dc.contributor.googleauthor | Heon Yoo | - |
dc.contributor.googleauthor | Yong-Kil Hong | - |
dc.contributor.googleauthor | Eun-Young Kim | - |
dc.contributor.googleauthor | Dong-Eun Lee | - |
dc.contributor.googleauthor | Jungnam Joo | - |
dc.contributor.googleauthor | Yu Jung Kim | - |
dc.contributor.googleauthor | Gheeyoung Choe | - |
dc.contributor.googleauthor | Byung Se Choi | - |
dc.contributor.googleauthor | Seok-Gu Kang | - |
dc.contributor.googleauthor | Jeong Hoon Kim | - |
dc.contributor.googleauthor | Chae-Yong Kim | - |
dc.identifier.doi | 10.4143/crt.2019.421 | - |
dc.contributor.localId | A00036 | - |
dc.contributor.localId | A03470 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 31671938 | - |
dc.subject.keyword | 1p/19q co-deletion | - |
dc.subject.keyword | Adjuvant treatment | - |
dc.subject.keyword | Anaplastic glioma | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Temozolomide | - |
dc.contributor.alternativeName | Kang, Seok Gu | - |
dc.contributor.affiliatedAuthor | 강석구 | - |
dc.contributor.affiliatedAuthor | 장종희 | - |
dc.citation.volume | 52 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 505 | - |
dc.citation.endPage | 515 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.52(2) : 505-515, 2020-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.